FOLD - Amicus Therapeutics Q3 2021 Earnings Preview
Amicus Therapeutics (NASDAQ:FOLD) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.18 and the consensus Revenue Estimate is $80.33M (+19.1% Y/Y). Over the last 1 year, FOLD has beaten EPS estimates 25% of the time and has beaten revenue estimates 75% of the time. Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 3 upward revisions and 1 downward. With a Bullish rating, SA Contributor ONeil Trader recently wrote that the company has carved out Gene Therapy portfolio, reducing upside optionality.
For further details see:
Amicus Therapeutics Q3 2021 Earnings Preview